Eric Fossel is the CEO of BullseyeTx, the CEO of ImmunoOncholytics LLC, and Director of Research & Development at Novilla Pharmaceuticals. A lifelong researcher, Eric has devoted himself to furthering medicine, particularly the fields of pain management and cancer treatment.   Eric has held assistant and associate professorships in the departments of Biophysics and Radiology at Harvard Medical School. Following his extensive academic career, Eric founded Strategic Science and Technologies in 1994. As CEO, he saw breakthroughs in transdermal drug delivery. Eric also holds about 3 dozen patents.